Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CiplaLUX:CIPLA 96 Days Sales Outstanding is 74.14 as of Jun. 2026, which is 6% above its 10-year median of 69.75. GuruFocus rates LUX:CIPLA with a GF Score™ of 96/100 and a GF Value™ of $20.96. The stock has 3 warning signs investors should review. Among 947 Drug Manufacturers companies, Cipla ranks worse than 56.39% on this metric.
Cipla's average Accounts Receivable for the
three
months ended in Jun. 2026 was $605 Mil. Cipla's Revenue for the
three
months ended in Jun. 2026 was $745 Mil.
Hence, Cipla's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 74.14.
The historical rank and industry rank for Cipla's Days Sales Outstanding or its related term are showing as below:
LUX:CIPLA'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 57.98 Med: 69.75 Max: 87.91
Current: 78.47
During the past 13 years, Cipla's highest Days Sales Outstanding was 87.91. The lowest was 57.98. And the median was 69.75.
LUX:CIPLA's Days Sales Outstanding is ranked worse than 56.39% of 947
companies
in the Drug Manufacturers industry
Industry Median: 71.98
vs LUX:CIPLA: 78.47
Cipla's Days Sales Outstanding
increased
from Jun. 2025 (72.94) to Jun. 2026 (74.14).
Cipla (LUX:CIPLA) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Cipla Days Sales Outstanding Related Terms
Cipla Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Cipla's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LUX:CIPLA vs ZTS: Days Sales Outstanding Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Cipla's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cipla Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cipla's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Cipla's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cipla (LUX:CIPLA) has a Days Sales Outstanding of 74.14 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Cipla and its competitors. This is near median its historical median of 69.75. Over the past decade, Cipla's Days Sales Outstanding has ranged from 57.98 to 87.91. According to the industry distribution chart, Cipla ranks #534 out of 947 companies in the Drug Manufacturers industry, placing it in the top 56.4%.
Is Cipla's Days Sales Outstanding too high?
Cipla's current Days Sales Outstanding of 74.14 is near median its 10-year median of 69.75. Over the past 10 years, this metric has ranged from a low of 57.98 to a high of 87.91. The Drug Manufacturers industry median Days Sales Outstanding is 71.98. Cipla's value of 74.14 is 3% above this industry median. Based on the distribution chart, Cipla ranks #534 out of 947 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Cipla has a GF Score™ of 96/100, reflecting its overall financial health beyond just this single metric.
How does Cipla's Days Sales Outstanding compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cipla ranks #534 out of 947 companies for Days Sales Outstanding. This places Cipla in the lower half of its industry. The industry median Days Sales Outstanding is 71.98. Cipla's value of 74.14 is 3% above this benchmark. Historically, Cipla's own Days Sales Outstanding has ranged from 57.98 to 87.91 over the past decade. While the company's 10-year median is 69.75 vs. the industry median of 71.98, Cipla has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 71.98, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cipla's current Days Sales Outstanding of 74.14 is 3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Cipla and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 71.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cipla's current Days Sales Outstanding is 74.14, which is near median its own 10-year median of 69.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cipla stock overvalued right now?
Cipla (LUX:CIPLA) has a current Days Sales Outstanding of 74.14. The stock's GF Value™ is $20.96, compared to a current price of $18.10 — trading 13.6% below its estimated fair value. The current Days Sales Outstanding is 74.14, which is near median its 10-year median of 69.75 and 3% above the Drug Manufacturers industry median of 71.98. Cipla's overall GF Score™ is 96/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Cipla (LUX:CIPLA), the current Days Sales Outstanding is 74.14 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cipla (LUX:CIPLA) Overvalued in 2026?
Based on GuruFocus' analysis, Cipla stock appears to be undervalued.
The current stock price of $18.10 is trading 13.6% below its estimated GF Value™ of $20.96.
Key valuation signals for LUX:CIPLA:
Days Sales Outstanding: 74.14 (near median its 10-year median of 69.75)
GF Value™: $20.96 vs. price of $18.10 (13.6% below fair value)
Industry Position: 3% above the Drug Manufacturers median (#534 of 947)
No single metric tells the full story. See the LUX:CIPLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cipla Ltd is a drug manufacturing company that focuses on a variety of pharmaceutical products. The company's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments. The bulk of its sales are generated in India, although it maintains a large world-wide presence. Cipla's growth plan focuses on new product launches. It has two segments Pharmaceuticals and new ventures. It derives maximum revenue from Pharmaceuticals Segment.
96GF Score
Get the complete analysis for LUX:CIPLA
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LUX:CIPLA has been successfully added to your 
